



CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

APPLICANT: Garth Powis
TITLE: USES OF THIOREDOXIN
SERIAL NO. 10/600,957
ATTORNEY REF: 126387.530
DATE OF DEPOSIT: January 5, 2004

I HEREBY CERTIFY THAT THIS INFORMATION DISCLOSURE STATEMENT TOGETHER WITH THE DOCUMENTS CITED THEREIN IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE VIA FIRST CLASS MAIL UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO COMMISSIONER FOR PATENTS, MAIL STOP DD, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Jennifer Martinez

(Typed or printed name of person mailing paper or fee)

Documents Enclosed:

1. Information Disclosure Statement with cited references;
2. Certificate of Mailing;
3. Postcard

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

POWIS, Garth

Serial No. 10/600,957

Filed: June 20, 2003

For: USES OF THIOREDOXIN

:

:

: Group Art Unit: 1642

: Examiner: Not yet assigned

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. Copies are provided. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.



AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to deposit account no. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP

A handwritten signature in black ink that reads "Raymond A. Miller".

Raymond A. Miller
Registration No. 42,891

Pepper Hamilton LLP
One Mellon Bank Center
50th Floor
500 Grant Street
Pittsburgh, PA 15219
Telephone: (412) 454-5813
Facsimile: (412) 281-0717
Date: January 5, 2004



Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known				
				Application Number		10/600,957		
				Filing Date		June 20, 2003		
				First Named Inventor		POWIS, Garth		
				Group Art Unit		1642		
Examiner Name		Not yet assigned						
Sheet	1	of 2		Attorney Docket Number		126387.530		
U.S. PATENT DOCUMENTS								
Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Number	Kind Code (if known)					
		20030223980		Powis	12-04-2003			
		20020055131		Powis	05-09-2002			
FOREIGN PATENT DOCUMENTS								
Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
		PCT	US97-22292		POWIS			
		WO	91 04320		Aktibolaget, Astra	4/4/1991		
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.						
		Baker, A., et al.: "Thioredoxin, a gene found overexpressed in human cancer" Cancer Research 57(22):5162-5167 (1997)						
		Powis, G., et al.: "Selenium and the Thioredoxin Redox System" Oncology Research 9(6-7):303-312 (1997)						
		Gallegos, A., et al.: "Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells" Cancer Research 56(24):5765-5770 (1996)						
		Berggren, M., et al.: "Thioredoxin and Thioredoxin Reductase Gene Expression in Human Tumors and Cell Lines" Anticancer Research 16:3459-66, XP002062159 (Nov.-Dec. 1996)						
		Gasdaska, J.R., et al.: Cell Growth Differentiation (December 1995)						
		Tockman, et al.: Cancer Research (Suppl) 52: 2715-2718 (1992)						
		Oblong, J.E.: Cancer Chemoth Pharmacol, 34:434-438 (1994)						
		Gura: Science 278:1041-1042 (1997)						
		Jain: Sci. Am, 271:58-65 (1994)						
		Gasdaska, J.R.: Biochem Pharmacol; 52:1741-1747 (1996)						
		Hartwell, et al: Science: 278:1064-1068 (1997)						
		Kirkpatrick, D.L., "Mechanisms of Inhibition of the Thioredoxin Growth Factor System by Antitumor 2-Imidazolyl Disulfides" Biochemical Pharmacology: 55: 987-996 (1998)						
		Kirkpatrick, D. L., et al., "Stimulation of Apoptosis by a Redox Active Disulfide" Proc. Am. Association, Cancer Res. 36 (1995): 2541						
		Drexler, et al. Leukemia and Lymphoma, 9:1-25 (1993)						
		Embleton, et al.: Immunol. Ser. 23:181-207 (1984)						
		Curti, et al.: Crit. Rev. in Oncology/Hematology, 14:29-39 (1993)						
		Mustafa O., et al.: International Journal of Oncology, 8(5):883-888 (1996)						
		Freshney: Culture of Animal Cells, a Manual of Basic Technique, Alan R. Liss, Inc., Pg. 4 (1983)						
		Powis, G., et al.: Thioredoxin Redox Signalling: a Novel Target for Anti-Cancer Drug Development, Anti-Cancer Drugs, 7:121-126 (1996)						
		Mau, B.L., et al.: Biochem. Pharmacol., 43: 1613-1620 (1992)						

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/600,957
		Filing Date	June 20, 2003
		First Named Inventor	POWIS, Garth
		Group Art Unit	1642
		Examiner Name	Not yet assigned
		Attorney Docket Number	126387.530
		Schallreuter, K.U. , Biochem Biophys Acta, 1504: 14-20 (1990)	
		Powis, et al., Oncology Research, 6 (10-11):539-44	
		Gadaska, P.Y., et al.: Biochem Biophys ACTA 1218:292-296 (1994)	
Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.